Visby Medical™, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to ...

Cairo: Kuwait has announced new health regulations for people travelling from the country to Saudi Arabia to perform the ...

Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, ...

Using a common antibiotic following sex can dramatically reduce a person’s risk of some sexually transmitted infections (STIs ...

Aptitude is dedicated to democratizing diagnostics through innovative, accessible testing solutions. The company's Metrix ...

The Global Antibiotic Research Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel ...

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.

SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.

The emergence of Neisseria gonorrhoeae strains resistant to ceftriaxone, the last reliable treatment, poses significant ...

Shares of Evaxion Biotech A/S EVAX rose sharply in today's pre-market trading after the company applied for a patent for vaccines targeting Neisseria gonorrhoeae. Evaxion Biotech shares jumped 62% ...